ASH 2023 | ctDNA allows for the prediction of outcomes following liso-cel infusion in patients with LBCL
Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, discusses how circulating tumor DNA (ctDNA) dynamics allowed for the prediction of outcomes in patients with large B-cell lymphoma (LBCL) who were treated with lisocabtagene maraleucel (liso-cel) in the Phase 3 TRANSFORM study (NCT03575351). In some patients, levels of ctDNA could discern therapeutic success or failure within 15 days of liso-cel infusion. Dr Alizadeh highlights that ctDNA may be a valuable biomarker for disease surveillance and comments on its relationship with PET/CT data. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
